Our team
Built by pioneers
of genetic medicine.
Our team brings the experience and conviction to shape the next era of genetic medicine. From early gene therapy breakthroughs to the development of first-in-class mRNA vaccines and targeted therapies, we have repeatedly translated cutting-edge science from the lab to the clinic. Collectively, we have translated many advanced therapies from bench to bedside, and contributed to multiple approved genetic medicines.
Building on this foundation, we applied the same rigor to the development of our transformative delivery platform. RNA therapeutics are still at an early inflection point, and we are committed to defining a new class of medicines that expands what’s possible for patients.
Leadership Team
Ali Nahvi, PhD
Chief Technology Officer
Mike Klichinsky, PhD
Chief Scientific Officer
Ben Adler, PhD
Chief Business Officer
Raffaella Toso, PhD
VP of BD and Corporate Strategy
Board of Directors
Issi Rozen
Chairperson
General Partner,
Google Ventures
Vineeta Agarwala, MD, PhD
Director
General Partner,
a16z
Lawrence Klein, PhD
Independent Director
Oruka Therapeutics
Jeff Marrazzo
Independent Director
Spark Therapeutics
Federico Mingozzi, PhD
Director
Nava Therapeutics
James Dahlman, PhD
Director
Co-Founder and CSO,
Readout Capital
Jessica Alston, PhD
Observer
Partner,
F-Prime
Robin Praeger
Observer
Advisor,
Versant
We believe the future of genetic
medicine lies in in vivo approaches.
Scalable delivery, repeat dosing, and precise cell targeting will make these therapies broadly viable and accessible to patients. Our team brings the experience and conviction to shape the next era of genetic medicine.
Investors
